566905-62-2

Upstream product

• 4304-12-5 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 27851-29-2 benzyl 2,3,4-tri-O-benzyl-D-glucopyranoside 
• 530-62-1 1,1'-carbonyldiimidazole 
• 27851-28-1 (2R,3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran 
• 39687-20-2 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol 

Downstream Products

• 566905-64-4 benzyl 2,3,4-tri-O-benzyl-6-O-[N-(3,4-dibenzyloxyphenylethyl)aminocarbonyl]-β-D-glucopyranoside 
• 1187036-97-0 benzyl 2,3,4-tri-O-benzyl-6-O-(N-(2-ethyl-2,8-diazaspiro[4,5]decane-1,3-dione)aminocarbonyl)-β-D-glucopyranoside 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Synthesis of glycosyl derivatives as dopamine prodrugs: Interaction with glucose carrier GLUT-1

Glucosyl dopamine (DA) derivatives may represent a new class of DA prodrugs that would interact with glucose transporter GLUT-1, present in the blood-brain barrier, and generate DA in the brain. Therefore, compounds bearing the sugar moiety linked to eith